- Did you mean
- laboratoria-confirmed
Search results - 141 results
Development of a monoclonal antibody sandwich ELISA for the determination of antigen content and quality in diphtheria vaccines.
control of diphtheria vaccines by both manufacturers and national control laboratories relies heavily on in vivo assays to confirm potency. As part of the VAC2VAC project we have developed a monoclonal ...
Factors underlying COVID-19 booster vaccine uptake among adults in Belgium
study aimed to investigate factors influencing the uptake of first and second COVID-19 booster vaccines among adults in Belgium, particularly age, sex, region of residence and laboratory confirmed ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed ...
Evaluation of a point-of-care test for the diagnosis of Taenia solium neurocysticercosis in rural southern Tanzania: a diagnostic accuracy study.
test had CT-confirmed neurocysticercosis. The TS POC test yielded a sensitivity of 49% (uncertainty interval [UI] 41-58) for neurocysticercosis. Sensitivity was similar to that of the rT24H- EITB (44%, ...
Epidemiology of COVID-19 mortality in Belgium from wave 1 to wave 7 (March 2020 – 11 September 2022)
was an even distribution (50.2% and 48.7% respectively). Case classification 87.7% of the COVID-19 deaths in Belgium were laboratory-confirmed cases. In 2021 and 2022 around 96% of the COVID-19 deaths ...
Homologous versus heterologous prime-boost COVID-19 vaccination: impact on clinical severity of Omicron among hospitalized COVID-19 patients in Belgium
confirmed by whole genome sequencing and vaccinated with a homologous (mRNA for prime/mRNA for boost) or heterologous (viral vector for prime/mRNA for boost) prime-boost vaccination schedule were included in ...
Towards clinical breakpoints for non-tuberculous mycobacteria- Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
Mycobacterium abscessus (MAB) obtained by commercial broth microdilution (SLOMYCOI and RAPMYCOI) from 12 laboratories. Epidemiological cut-off values (ECOFF s) and tentative ECOFF s (TECOFF s) were determined by ...
Development of strain-level shotgun metagenomics approaches to detect and characterize microbiological contaminants in the context of food safety
laboratories in the future. The method was first tested on minced beef spiked with shiga toxin-producing E.coli (STEC) at very low level (5 CFU /25g). After enrichment for 16 or 24 hours in buffered peptone ...
Development of a Taxon-Specific Real-Time Polymerase Chain Reaction Method to Detect Trichoderma reesei Contaminations in Fermentation Products
method was assessed as specific and sensitive (LOD95 % = eight copies). In addition, the developed real-time PCR TR method performance was confirmed to be in line with the “Minimum Performance Requirements ...
Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.
on in-hospital deaths of laboratory-confirmed influenza patients in 11 European Union countries from 2010/11 to 2019/20.MethodsCase-based surveillance data from hospitalised patients with known age, ...